170 related articles for article (PubMed ID: 34236573)
1. Pre-diagnosis neutrophil-to-lymphocyte ratio and mortality in individuals who develop lung cancer.
Grieshober L; Graw S; Barnett MJ; Goodman GE; Chen C; Koestler DC; Marsit CJ; Doherty JA
Cancer Causes Control; 2021 Nov; 32(11):1227-1236. PubMed ID: 34236573
[TBL] [Abstract][Full Text] [Related]
2. Methylation-derived Neutrophil-to-Lymphocyte Ratio and Lung Cancer Risk in Heavy Smokers.
Grieshober L; Graw S; Barnett MJ; Thornquist MD; Goodman GE; Chen C; Koestler DC; Marsit CJ; Doherty JA
Cancer Prev Res (Phila); 2018 Nov; 11(11):727-734. PubMed ID: 30254071
[TBL] [Abstract][Full Text] [Related]
3. AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality.
Grieshober L; Graw S; Barnett MJ; Thornquist MD; Goodman GE; Chen C; Koestler DC; Marsit CJ; Doherty JA
BMC Cancer; 2020 Sep; 20(1):905. PubMed ID: 32962699
[TBL] [Abstract][Full Text] [Related]
4. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
5. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
Liu D; Huang Y; Li L; Song J; Zhang L; Li W
BMC Cancer; 2017 Dec; 17(1):882. PubMed ID: 29268698
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study.
Kang J; Chang Y; Ahn J; Oh S; Koo DH; Lee YG; Shin H; Ryu S
Int J Cancer; 2019 Dec; 145(12):3267-3275. PubMed ID: 31454064
[TBL] [Abstract][Full Text] [Related]
7. DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes.
Koestler DC; Usset J; Christensen BC; Marsit CJ; Karagas MR; Kelsey KT; Wiencke JK
Cancer Epidemiol Biomarkers Prev; 2017 Mar; 26(3):328-338. PubMed ID: 27965295
[No Abstract] [Full Text] [Related]
8. Methylation-derived inflammatory measures and lung cancer risk and survival.
Zhao N; Ruan M; Koestler DC; Lu J; Salas LA; Kelsey KT; Platz EA; Michaud DS
Clin Epigenetics; 2021 Dec; 13(1):222. PubMed ID: 34915912
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.
Omenn GS; Goodman GE; Thornquist MD; Balmes J; Cullen MR; Glass A; Keogh JP; Meyskens FL; Valanis B; Williams JH; Barnhart S; Cherniack MG; Brodkin CA; Hammar S
J Natl Cancer Inst; 1996 Nov; 88(21):1550-9. PubMed ID: 8901853
[TBL] [Abstract][Full Text] [Related]
10. Telomere Length and Lung Cancer Mortality among Heavy Smokers.
Doherty JA; Grieshober L; Houck JR; Barnett MJ; Tapsoba JD; Thornquist M; Wang CY; Goodman GE; Chen C
Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):829-837. PubMed ID: 29743162
[No Abstract] [Full Text] [Related]
11. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
12. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
Rice SJ; Belani CP
PLoS One; 2021; 16(12):e0260988. PubMed ID: 34855926
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.
Suzuki R; Wei X; Allen PK; Cox JD; Komaki R; Lin SH
Clin Lung Cancer; 2019 Mar; 20(2):117-123. PubMed ID: 30611672
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer.
Mizuguchi S; Izumi N; Tsukioka T; Komatsu H; Nishiyama N
J Cardiothorac Surg; 2018 Jun; 13(1):78. PubMed ID: 29945635
[TBL] [Abstract][Full Text] [Related]
15. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer.
Suzuki R; Lin SH; Wei X; Allen PK; Welsh JW; Byers LA; Komaki R
Radiother Oncol; 2018 Mar; 126(3):499-505. PubMed ID: 29398150
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer.
Käsmann L; Bolm L; Schild SE; Janssen S; Rades D
Lung; 2017 Apr; 195(2):217-224. PubMed ID: 28154994
[TBL] [Abstract][Full Text] [Related]
18. Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival.
Wiencke JK; Koestler DC; Salas LA; Wiemels JL; Roy RP; Hansen HM; Rice T; McCoy LS; Bracci PM; Molinaro AM; Kelsey KT; Wrensch MR; Christensen BC
Clin Epigenetics; 2017; 9():10. PubMed ID: 28184256
[TBL] [Abstract][Full Text] [Related]
19. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis.
Lu Y; Jiang J; Ren C
PLoS One; 2020; 15(4):e0230979. PubMed ID: 32241019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
